2015 Press Releases
Keyword Search
 
2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004
DateTitle 
08/27/15WuXi PharmaTech's STA Subsidiary Receives First Approval from Japanese Regulatory Authorities
SHANGHAI, Aug. 27, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that its small-molecule process development and manufacturing subsidiary Shanghai SynTheAll Pharmaceutical Co., Ltd. (STA) received its first approval from the Japan PMDA for the manufacture of the GMP intermediate of a branded commercial drug in July. ST... 
Printer Friendly Version
08/25/15WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm
SHANGHAI, Aug. 25, 2015 /PRNewswire/ --  WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, and Lee's Pharmaceutical Holdings Ltd. ("Lee's Pharm," Hong Kong Exchange Stock Code: 0950), a research-based biopharmaceutical company headquartered in Hong Kong with 20 years of operations in China, today announced that the two companies have signed an agreement where... 
Printer Friendly Version
08/14/15Wuxi Pharmatech Enters Into Definitive Merger Agreement
SHANGHAI, Aug. 14, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced that it has entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") with New WuXi Life Science Limited ("Parent") and WuXi Merger Limited ("Merger Sub"), a wh... 
Printer Friendly Version
08/13/15WuXi PharmaTech Announces Second-Quarter 2015 Results
SHANGHAI, Aug. 13, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc.("WuXi") (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for the second quarter of 2015.  Second-Quarter 2015 Highlights Net Revenues Increased 18.8% Year Over Year to $194.1 Million Net Revenues for Laboratory Services Gre... 
Printer Friendly Version
08/10/15WuXi PharmaTech and TruTag Technologies Complete Successful Testing of Edible On-Dose Authentication Solution for Pharmaceuticals
Covert, edible technology can be used to manage the pharmaceutical supply chain, prevent counterfeiting or diversion, and provide product informatics SHANGHAI and HONOLULU, Aug. 10, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, and TruTag Technologies, Inc., developer of an innovative edible security platform for pharmaceuticals,... 
Printer Friendly Version
07/29/15WuXi PharmaTech Schedules Second-Quarter 2015 Earnings Release
SHANGHAI, July 29, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States, today announced that it will release financial results for the second-quarter of 2015 after the New York Stock Exchange closes on Thursday, August 13, 2015 (which will be Friday morning, August 14, 2015 Shanghai time). The e... 
Printer Friendly Version
07/10/15WuXi PharmaTech's China-Based Small-Molecule Manufacturing Subsidiary, STA, Enters into Private Placement Agreement
SHANGHAI, July 10, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced that SynTheAll Pharmaceutical Co. Ltd. (STA), WuXi's small-molecule manufacturing subsidiary, has entered into an agreement in connection with a planned private placement of 7,160,000 common shares of STA sto... 
Printer Friendly Version
06/04/15WuXi AppTec Partners with Fudan University and the Collaborative Innovation Center of Genetics and Development
China's leading research and innovation cluster will use WuXi NextCODE technology, the world's most proven genomics system, to advance precision medicine SHANGHAI, CAMBRIDGE, Mass. and REYKJAVIK, Iceland, June 4, 2015 /PRNewswire/ -- WuXi AppTec today announced a partnership with Fudan University to bring WuXi NextCODE's world-leading population human genomics database system and integrated research and clinical solutions to the Fudan-led Collaborative Innovation Center of Genetics and Deve... 
Printer Friendly Version
06/03/15WuXi NextCODE Wins Genomics England Clinical Interpretation Tender in Both Rare Disease and Cancer
... 
Printer Friendly Version
05/21/15Fosun Pharma, HOPU Investments, CEL Healthcare Fund, and WuXi PharmaTech to Jointly Acquire U.S. Innovative Biotechnology Company Ambrx
SHANGHAI, May 21, 2015 /PRNewswire/ -- A consortium ("the Consortium") consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU Investments, China Everbright Limited's healthcare fund ("CEL Healthcare Fund"), and WuXi PharmaTech announced today that the Consortium has signed a merger agreement pursuant to which the Consortium will acquire Ambrx Inc. The transaction is expected to close in the second quarter of 2015, subject to receipt of certain regulatory approvals and s... 
Printer Friendly Version
05/21/15WuXi Launches e-Commerce Platform for Chemistry Products
SHANGHAI, May 21, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced the launch of LabNetwork (www.labnetwork.com). LabNetwork is a global e-Commerce platform for connecting buyers and sellers of research chemicals and reagents. Backed by WuXi's world-class expertise in chemist... 
Printer Friendly Version
05/13/15WuXi PharmaTech Announces First-Quarter 2015 Results
SHANGHAI, May 13, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for the first quarter of 2015.  First-Quarter 2015 Highlights Net Revenues Increased 22.7% Year Over Year to $180.0 Million Net Revenues for Laboratory Services Grew 20.6%... 
Printer Friendly Version
05/13/15WuXi PharmaTech Announces Formation of a Special Committee to Evaluate Non-Binding Proposal
SHANGHAI, May 13, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") (NYSE:WX), a leading global contract R&D services provider, today announced that, in response to a preliminary non-binding proposal letter, dated April 29, 2015, received by the Company's board of directors (the "Board") from Dr. Ge Li (the "Chairman"), founder, chairman and chief executive officer of the Company, and Ally Bridge Group Capital Partners to acquire the Company in a "going private" tr... 
Printer Friendly Version
04/30/15WuXi Biologics Begins Construction of the World's Largest Mammalian Cell Culture Manufacturing Facility Using Disposable Bioreactors
SHANGHAI, April 30, 2015 /PRNewswire/ -- WuXi Biologics, a wholly owned subsidiary of WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries, announced today that construction has begun on a new $150 million biologics manufacturing facility in Wuxi city. When complete, this new facility will be the largest mammalian cell culture manufacturing facil... 
Printer Friendly Version
04/30/15WuXi PharmaTech Announces Receipt of Proposal
SHANGHAI, April 30, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") (NYSE:WX), a leading global contract R&D services provider, today announced that its board of directors has received a preliminary non-binding proposal letter, dated April 29, 2015, from a consortium (the "Consortium") led by Dr. Ge Li (the "Chairman"), founder, chairman and chief executive officer of the Company, and Ally Bridge Group Capital Partners ("ABG") that proposes a transaction (the "Tr... 
Printer Friendly Version
04/23/15WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release
SHANGHAI, April 23, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States, today announced that it will release financial results for the first quarter of 2015 after the New York Stock Exchange closes on Wednesday, May 13, 2015 (which will be Thursday morning, May 14, 2015 Shanghai time). The earn... 
Printer Friendly Version
04/22/15Big Data and Genomics Meet the Cloud: the First Unified Global Platform for Precision Medicine
$15 million investment and alliance puts WuXi NextCODE's unrivalled genome analytics on DNAnexus's cloud platform, seamlessly linked to WuXi PharmaTech's China and global R&D platform SHANGHAI; CAMBRIDGE, Mass.; and MOUNTAIN VIEW, Calif., April 22, 2015 /PRNewswire/ – WuXi PharmaTech (Cayman) Inc. (NYSE: WX), whose leading open-access R&D capability and technology platform serves the pharmaceutical, biotechnology and medical device industries, announced today that its wholly owned s... 
Printer Friendly Version
04/15/15WuXi PharmaTech Files 2014 Annual Report on Form 20-F
SHANGHAI, April 15, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) today announced that it filed its annual report on Form 20-F for the year ended December 31, 2014, with the Securities and Exchange Commission.  The annual report can be accessed on WuXi PharmaTech's website at http://www.wuxiapptec.com under the Investor Relations section.  WuXi PharmaTech will provide a hard copy of its annual report on Form 20-F containing complete audited financial statements free of charge to ... 
Printer Friendly Version
04/08/15Nobel Prize Laureate Professor Barry Sharpless Visits WuXi AppTec Headquarters in Shanghai
SHANGHAI, April 8, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, announced today that Professor Barry Sharpless visited WuXi AppTec's Shanghai headquarters on April 8 and gave an inspiring scientific lecture. Professor Sharpless holds the W. M. Keck professorship in chemistry at The Scripps Research Institute. His visit was part of the... 
Printer Friendly Version
04/02/15WuXi PharmaTech Lists Shares of Small-Molecule Manufacturing Subsidiary STA on New Third Board in China
SHANGHAI, April 2, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, announced today that its wholly owned subsidiary SynTheAll Pharmaceutical Co. Ltd. ("STA") has received approval from the National Equities Exchange and Quotations ("NEEQ") in China to list its shares on the New Third Board, the over-the-counter (OTC) stock exchange in Ch... 
Printer Friendly Version
03/27/15Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA
SHANGHAI, March 27, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries, announced today that an Investigational New Drug (IND) application for WuXi MedImmune's novel anti-IL6 monoclonal antibody for rheumatoid arthritis has been accepted for review by the China Food and Drug Administration (CFDA).  In September 2012, MedImmune, t... 
Printer Friendly Version
03/25/15Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide
Clinicians, researchers and population genomics programs around the world can build on this unique national effort to use the genome to better prevent, diagnose and treat disease SHANGHAI, CAMBRIDGE, Massachusetts, and REYKJAVIK, 25 March 2015 – WuXi NextCODE, which provides comprehensive capabilities for using the genome to create better medicine, today congratulated the scientists at deCODE genetics on their publication of the largest studies of whole-genome data yet undertaken. The studies ... 
Printer Friendly Version
03/12/15WuXi PharmaTech To Build New Cell Therapy Manufacturing Facility for CAR T Cells and Other Cancer Immunotherapies
SHANGHAI, March 12, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, announced today that it will soon begin construction of a new, 145,000-square-foot cGMP facility in Philadelphia for the manufacture of cell therapy products. This facility is designed for cell therapy products that contain viral vectors such as chimeric antigen recepto... 
Printer Friendly Version
03/05/15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results
SHANGHAI, March 5, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for the fourth quarter and full year of 2014.  Fourth-Quarter 2014 Highlights Net Revenues Increased 21.3% Year Over Year to $190.6 Million Laboratory Services Net Revenues Gr... 
Printer Friendly Version
02/27/15WuXi Congratulates TaiMed Biologics on Receiving Breakthrough Therapy Designation from U.S. FDA
SHANGHAI, Feb. 27, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, congratulates our partner TaiMed Biologics for receiving breakthrough therapy designation from the U.S. FDA for ibalizumab (TMB355). The FDA designates a drug as a breakthrough therapy if it is intended, alone or in combinat... 
Printer Friendly Version
02/17/15WuXi PharmaTech Enters into Syndicated Loan Agreement
SHANGHAI, Feb. 17, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, announced that it has entered into a syndicated loan facility to borrow up to $165 million from a consortium of banks in Asia led by Citibank. The borrowing will incur interest at a rate of LIBOR plus 2.89%, including all ex... 
Printer Friendly Version
02/13/15WuXi PharmaTech Schedules Fourth-Quarter 2014 Earnings Release
SHANGHAI, Feb. 13, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States, today announced that it will release financial results for the fourth quarter of 2014 after the New York Stock Exchange closes on Thursday, March 5, 2015 (which will be Friday morning, March 6, 2015 Shanghai time). The earni... 
Printer Friendly Version
02/06/15WuXiPRA Appoints Two Key Executives
SHANGHAI, Feb. 6, 2015 /PRNewswire/ -- WuXiPRA, a leading clinical services company with operations in the greater China region, today announced appointments of two key executives. Liedong Xu was named Executive Vice President and Chief Operations Officer. He brings 22 years of experience in the pharmaceutical and medical device industries, including roles of increasing responsibility at MSD Allergan, Abbott Santen, and Merck Serono. Jason Wu was appointed Executive Vice President and Chief Medi... 
Printer Friendly Version
01/30/15WuXi PharmaTech's Small-Molecule Manufacturing Subsidiary STA Wins CMO Leadership Award
SHANGHAI, Jan. 30, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, announced today that SynTheAll Pharmaceutical Co., Ltd. (STA), WuXi's small-molecule manufacturing subsidiary, has won a 2015 CMO Leadership Award, which is presented by Life Science Leader magazine based on research conduct... 
Printer Friendly Version
01/09/15WuXi PharmaTech Provides Update of 2014 Financial Guidance, to Present at J.P. Morgan Healthcare Conference
SHANGHAI , Jan. 9, 2015 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced that it has updated its 2014 financial guidance. The company expects to achieve total revenues for full-year 2014 of approximately $674 million, compared to previous guidance of $670-672 million. The company expects to ach... 
Printer Friendly Version
01/09/15WuXi PharmaTech Acquires NextCODE Health to Create Global Leader in Genomic Medicine
NextCODE and WuXi's Genome Center will offer comprehensive clinical, research, and diagnostic testing products and services worldwide SHANGHAI, Jan. 9, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, announces that it has acquired NextCODE Health, a leading genomic analysis... 
Printer Friendly Version
01/05/15WuXi PharmaTech Statement on Recent News Report
SHANGHAI, China, January 5, 2015 /PRNewswire/ -- WuXi PharmaTech stated today that a recent news report regarding purported FDA communication with a company named Novacyl Wuxi Pharmaceutical does not relate to WuXi PharmaTech.... 
Printer Friendly Version
01/05/15WuXi Launches Mobile App to Enable Chemistry-on-the-Go
SHANGHAI, Jan. 5, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States, announced the launch of WuXi V-Lab, the first mobile app available to the global research community in need of small-molecule compound synthesis.  WuXi V-Lab allows customers to request organic compound synthesis through a mo... 
Printer Friendly Version